Combined delivery of BCNU and VEGF siRNA using amphiphilic peptides for glioblastoma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yi, Na | - |
dc.contributor.author | Oh, Binna | - |
dc.contributor.author | Kim, Hyun Ah | - |
dc.contributor.author | Lee, Minhyung | - |
dc.date.accessioned | 2022-07-16T06:07:56Z | - |
dc.date.available | 2022-07-16T06:07:56Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2014-02 | - |
dc.identifier.issn | 1061-186X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/160711 | - |
dc.description.abstract | Combined delivery of chemical drug and therapeutic gene has been introduced as an efficient method for the treatment of cancers such as glioblastoma. In this study, bis-chloroethylnitrosourea (BCNU) and vascular endothelial growth factor (VEGF) small interfering RNA (VEGFsiRNA) were co-delivered into C6 glioblastoma cells using a non-toxic peptide-based carrier. The R3V6 peptides, which are composed of 3-arginine and 6-valine, formed self-assembled micelles in aqueous solution. BCNU, a hydrophobic anti-cancer drug, was loaded into the hydrophobic core of the micelles, forming BCNU-loaded R3V6 micelles (R3V6-BCNU). In gel retardation assay, R3V6-BCNU formed a stable complex with siRNA. In vitro transfection assay showed that the VEGF-siRNA/R3V6-BCNU complex had the highest transfection efficiency into C6 cells at a 1: 20 weight ratio (VEGF-siRNA: R3V6-BCNU). In addition, the VEGF-siRNA/R3V6BCNU complexes had higher delivery efficiency than lipofectamine or naked siRNA. VEGF expressions were remarkably decreased by transfection of the VEGF-siRNA/R3V6 or VEGFsiRNA/ R3V6-BCNU complexes. Furthermore, R3V6-BCNU delivered BCNU more efficiently into the cells than BCNU only. Therefore, R3V6 delivered both VEGF-siRNA and BCNU efficiently into the glioblastoma cells. The results suggest that R3V6-BCNU may be useful for combined delivery of siRNA and chemical drug into cancer cells. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.title | Combined delivery of BCNU and VEGF siRNA using amphiphilic peptides for glioblastoma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Minhyung | - |
dc.identifier.doi | 10.3109/1061186X.2013.850502 | - |
dc.identifier.scopusid | 2-s2.0-84891799565 | - |
dc.identifier.wosid | 000329302400007 | - |
dc.identifier.bibliographicCitation | JOURNAL OF DRUG TARGETING, v.22, no.2, pp.156 - 164 | - |
dc.relation.isPartOf | JOURNAL OF DRUG TARGETING | - |
dc.citation.title | JOURNAL OF DRUG TARGETING | - |
dc.citation.volume | 22 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 156 | - |
dc.citation.endPage | 164 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | MALIGNANT GLIOMA | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | ANGIOGENESIS | - |
dc.subject.keywordPlus | DISEASES | - |
dc.subject.keywordPlus | RNA | - |
dc.subject.keywordPlus | DNA | - |
dc.subject.keywordAuthor | Combined delivery | - |
dc.subject.keywordAuthor | glioblastoma | - |
dc.subject.keywordAuthor | peptide micelles | - |
dc.subject.keywordAuthor | VEGF siRNA | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.3109/1061186X.2013.850502 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.